Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 158, Issue 4, 1998, Pages 1061-1067

  Archer, Stephen L ^a   Djaballah, Khier ^b   Humbert, Marc ^b   Weir, E Kenneth ^b   Fartoukh, Muriel ^b   Dall'ava Santucci, Josette ^b   Mercier, Jean Christophe ^b   Simonneau, Gerald ^b   Dinh Xuan, A Tuan ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; NITRIC OXIDE;

ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXERCISE; FEMALE; HUMAN; LUNG HEMODYNAMICS; MALE; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

EID: 0031770719     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.158.4.9802113     Document Type: Article

References (28)

1. VanItallie, T. B. 1996. Prevalence of obesity. Endocrin. Metab. Clin. North Am. 25:887-905.
2. Langreth, R. 1997. Critics claim diet clinics misuse obesity drugs. Wall Street Journal. March 31, 1997:B8.
3. Abenhaim, L., Y. Moride, F. Brenot, S. Rich, J. Benichou, X. Kurz, T. Higenbottam, C. Oakley, E. Wouters, M. Aubier, G. Simoneau, and B. Begaud. 1996. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med. 335:609-616.
4. Gurtner, H. 1979. Pulmonary hypertension, "plexogenic pulmonary arteriopathy" and the appetite depressant drug aminorex: post or propter. Bull. Eur. Physiopathol. Res. 15:897-923.
5. Mark, E. J., E. D. Patalas, H. T. Chang, R. J. Evans, and S. C. Kessler. 1997. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N. Engl. J. Med. 337:602-606.
6. Weir, E. K., H. L. Reeve, J. Huang, E. Michelakis, D. P. Nelson, V. Hampl, and S. L. Archer. 1996. Anorexic agents aminorex, fenfluramine and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 94:2216-2220.
7. Cheymol, G., J. Weissenburger, J. M. Poirier, and C. Gellee. 1995. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br. J. Clin. Pharmacol. 39:684-687.
8. Isaacson, T. C., V. Hampl, E. K. Weir, D. P. Nelson, and S. L. Archer. 1994. Increased endothelium-derived nitric oxide in hypertensive pulmonary circulation of chronically hypoxic rats. J. Appl. Physiol. 76: 933-940.
9. Archer, S. L. 1993. Measurement of nitric oxide in biological models. FASEB J. 7:349-360.
10. Dillon, W. C., V. Hampl, P. J. Shultz, J. B. Rubins, and S. L. Archer. 1996. Origins of breath nitric oxide in humans. Chest 110:930-938.
11. Riley, M. S., J. Pórszász, J. Miranda, M. P. K. J. Engelen, B. Brundage, and K. Wasserman. 1997. Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis. Chest 111:44-50.
12. Mlczoch, J., E. Weir, J. Reeves, and R. Grover. 1979. Long term effects of the anorectic agent fenfluramine alone and in combination with aminorex on pulmonary and systemic circulation of the pig. Basic Res. Cardiol. 74:313-320.
13. Naeije, R., P. Wauthy, M. Maggiorini, M. Leeman, and M. Delcroix. 1995. Effects of dexfenfluramine on hypoxic pulmonary vasoconstriction and embolic pulmonary hypertension in dogs. Am. J. Respir. Crit. Care Med. 151:692-697.
14. Forte, P., M. Copland, L. M. Smith, E. Mime, J. Sutherland, and N. Benjamin. 1997. Basal nitric oxide synthesis in essential hypertension. Lancet 349:837-842.
15. Xue, C., and R. A. Johns. 1996. Upregulation of nitric oxide synthase correlates temporally with onset of pulmonary vascular remodeling in the hypoxic rat. Hypertension 28:743-753.
16. Giaid, A., and D. Saleh. 1995. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333:214-221.
17. McQuillan, L. P., G. K. Leung, P. A. Marsden, S. K. Kostyk, and S. Kourembanas. 1994. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am. J. Physiol. 267: H1921-H1927.
18. Dinh-Xuan, A. T., T. W. Higenbottam, C. A. Clelland, J. Pepke-Zaba, G. Cremona, A. Y. Butt, S. R. Large, F. C. Wells, and J. Wallwork. 1991. Impairment of endothelium-dependent pulmonary-artery relaxation in chrome obstructive lung disease. N. Engl. J. Med. 324:1539-1547.
19. Dweik, R., D. Laskowski, H. Abu-Soud, F. Kaneko, R. Hutte, D. Stuehr, and S. Erzurum. 1998. Nitric oxide synthesis in the lung: regulation by oxygen through a kinetic mechanism. J. Clin. Invest. 101:660-666.
20. Kirchner, K. A., P. H. Scanlon, Jr., D. J. Dzielak, and R. L. Hester. 1993. Endothelium-derived relaxing factor responses in Doca-salt hypertensive rats. Am. J. Physiol. 265:R568-R572.
21. 2+/EDRF signaling are due to generation of superoxide anions. Diabetes 45:1386-1395.
22. Glasser, S. P., A. P. Selwyn, and P. Ganz. 1996. Atherosclerosis: risk factors and the vascular endothelium. Am. Heart J. 131:379-384.
23. Lundberg, J. O. N., E. Weitzberg, S. L. Nordvall, R. Kuylenstierna, J. M. Lundberg, and K. Alving. 1994. Primarily nasal origin of exhaled nitric oxide and absence in Kartagener's syndrome. Eur. Respir. J. 7:1501-1504.
24. Lundberg, J. O. N., T. Farkas-Szallasi, E. Weitzberg, J. Rinder, J. Lidholm, A. Anggard, T. Hokfelt, J. M. Lundberg, and K. Alving. 1995. High nitric oxide production in human paranasal sinuses. Nat. Med. 1:370-373.
25. Persson, M. G., N. P. Wiklund, and L. E. Gustafsson. 1993. Endogenous nitric oxide in single exhalations and the change during exercise. Am. Rev. Respir. Dis. 148:1210-1214.
26. Evrad, P., A. F. Allaz, and P. Urban. 1990. Myocardial infarction associated with the use of dexfenfluramine. B.M.J. 301:1049-1050.
27. Bailie. T. 1991. Fenfluramine-induced unstable angina pectoris. Can. J. Pharmacol. 44:211-215.
28. Connolly, H. M., J. L. Crary, M. D. McGoon, D. D. Hensrud, B. S. Edwards, W. D. Edwards, and H. V. Schaff. 1997. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337:581-588.